Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gower

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Allergy and Asthma Proceedings|May 16, 2012
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerationsRichard G Gower, William R Lumry, Mark A Davis-Lorton, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 5, 2009
When is prophylaxis for hereditary angioedema necessary?Timothy Craig, Marc Riedl, Mark S Dykewicz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 30, 2018
Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiencyTimothy Craig, Paula Busse, Richard G Gower, et al.
American Journal of Clinical Dermatology|May 15, 2023
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical StudyLawrence F Eichenfield, Richard G Gower, JinHua Xu, et al.
Internal Medicine Journal|April 17, 2004
Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approachN Horvath, U Hahn, D Joshua, et al.
The World Allergy Organization Journal|January 4, 2013
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategiesRichard G Gower, Paula J Busse, Emel Aygören-Pürsün, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedemaJonathan A Bernstein, Michael E Manning, Henry Li, et al.
Frontiers in Medicine|April 25, 2024
Unveiling APOL1 haplotypes in a predominantly African-American cohort of kidney transplant patients: a novel classification using probe-independent quantitative real-time PCRMurat Dogan, Christine Watkins, Holly Ingram, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
Unveiling APOL1 Haplotypes: A Novel Classification Through Probe-Independent Quantitative Real-Time PCRMurat Dogan, Christine Watkins, Holly Ingram, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Allergy and Asthma Proceedings|May 16, 2012
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerationsRichard G Gower, William R Lumry, Mark A Davis-Lorton, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 5, 2009
When is prophylaxis for hereditary angioedema necessary?Timothy Craig, Marc Riedl, Mark S Dykewicz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 30, 2018
Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiencyTimothy Craig, Paula Busse, Richard G Gower, et al.
American Journal of Clinical Dermatology|May 15, 2023
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical StudyLawrence F Eichenfield, Richard G Gower, JinHua Xu, et al.
Internal Medicine Journal|April 17, 2004
Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approachN Horvath, U Hahn, D Joshua, et al.
The World Allergy Organization Journal|January 4, 2013
Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategiesRichard G Gower, Paula J Busse, Emel Aygören-Pürsün, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 26, 2014
Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedemaJonathan A Bernstein, Michael E Manning, Henry Li, et al.
Frontiers in Medicine|April 25, 2024
Unveiling APOL1 haplotypes in a predominantly African-American cohort of kidney transplant patients: a novel classification using probe-independent quantitative real-time PCRMurat Dogan, Christine Watkins, Holly Ingram, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
Unveiling APOL1 Haplotypes: A Novel Classification Through Probe-Independent Quantitative Real-Time PCRMurat Dogan, Christine Watkins, Holly Ingram, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 3